title: Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy?
abstract: Cholinergic systems are markedly affected both in cortical and subcortical cerebral areas of patients with progressive supranuclear palsy (PSP). To determine whether it is possible to modify the clinical picture of PSP through the enhancement of brain cholinergic neurotransmission, we studied the effects of physostigmine, an anticholinesterase reference drug, on symptoms and brain glucose metabolism using [18F]fluorodeoxyglucose (FDG) and PET. Patients were evaluated blind in a randomized order with both placebo and physostigmine infusions after an individual determination of maximal tolerated dose. Under steady-state physostigmine infusions, although glucose consumption was not significantly modified, the entry of glucose from blood to brain was regionally increased from 8 to 32% of placebo values suggesting an increase in cerebral blood flow (CBF) or an increase in the activity of brain glucose transporter. Following physostigmine administration in the same patients: the errors in antisaccades during ocular movement testing were significantly reduced, a significant reduction in errors or performance was found in four out of seven neuropsychological tests, and motor disability was not significantly altered. Although the precise pathophysiology of these physostigmine-induced effects needs further investigations, our study suggests that part of the clinical symptomatology in PSP could be relieved by the enhancement of brain cholinergic neurotransmission.
authors.affiliation: INSERM U289, Nouvelle pharmacie, Hôpital de la Salpêtrière, France.
authors.forename: J
authors.initials: J
authors.lastname: Blin
authors.forename: P
authors.initials: P
authors.lastname: Mazetti
authors.forename: B
authors.initials: B
authors.lastname: Mazoyer
authors.forename: S
authors.initials: S
authors.lastname: Rivaud
authors.forename: S
authors.initials: S
authors.lastname: Ben Ayed
authors.forename: C
authors.initials: C
authors.lastname: Malapani
authors.forename: B
authors.initials: B
authors.lastname: Pillon
authors.forename: Y
authors.initials: Y
authors.lastname: Agid
mesh_terms: D000368:Aged; D001921:Brain / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005133:Eye Movements / Q000187:drug effects; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D009068:Movement / Q000187:drug effects; D009483:Neuropsychological Tests; D010275:Parasympathetic Nervous System / Q000503:physiopathology*; D010830:Physostigmine / Q000627:therapeutic use; D013494:Supranuclear Palsy, Progressive / Q000188:drug therapy / Q000503:physiopathology*; D009435:Synaptic Transmission
chemical_list: D010830:Physostigmine; D005947:Glucose